Global Cardiac Biomarker Market 2025-2035

Description

List of Tables

Cardiac Biomarker Market Size, Share & Trends Analysis Report by Type (Troponins (I and T), Creatine Kinase-MB (CK-MB), Myoglobin, and Natriuretic Peptides (BNP and NT-proBNP), and Ischemia-modified Albumin (IMA)) by Application (Acute Coronary Syndrome (ACS), Myocardial Infarction (Heart Attack), Congestive Heart Failure (CHF), and Others) and by End-User (Laboratory Testing, and Point-of-Care Testing) Forecast Period (2025-2035)

Industry Overview

Cardiac biomarker market was valued at $4.8 billion in 2024 and is projected to reach $20.7 billion by 2035, growing at a CAGR of 14.3% during the forecast period (2025-2035). Cardiac biomarkers are enzymes, proteins, or hormones released in the bloodstream when the heart is damaged or stressed. A cardiac biomarker test is performed to diagnose acute coronary syndrome and cardiac ischemia by measuring the levels of cardiac biomarkers. The cardiac biomarkers include troponin (I and T), creatinine kinase (CK), CK-MB, and myoglobin. An increase in one or more of these biomarkers in the blood can identify potential heart damage in a patient. This allows for rapid and accurate diagnosis and suitable treatment for their condition. The increasing incidences of heart attacks increase the demand for testing cardiac biomarkers in patients suffering from chest pain and other symptoms. Cardiovascular disease is the leading cause of premature deaths globally, necessitating preventive care. The growing demand for point-of-care diagnostics also boost the market. Cardiac biomarker tests can also significantly reduce the total healthcare expenditure.

Market Dynamics

Growing Research and Development

The escalating global burden of CVDs and advancements in biotechnology and diagnostic tools have fueled intensive research and development (R&D) in this field, thereby preventing future cardiac biomarkers market growth opportunities. Several researchers are investigating the role of cardiac biomarkers in the early detection of heart diseases. Novel biomarkers such as microRNAs, genetic variants, metabolomics markers, etc., have been researched and could revolutionize CVD diagnosis and management. Also, well-proven markers are investigated for other pathophysiological pathways, including inflammation, oxidative stress, and fibrosis, that are pivotal in cardiovascular disease. Additionally, biomarkers are developed to eventually reduce the cost of testing of CVDs. Novel devices have been invented to detect cardiac biomarkers precisely and in less time. Hence, biomarkers are the most rapidly evolving field, resulting in novel findings for better treatment outcomes.

High Cost of Advanced Diagnostic Tests

The development and implementation of advanced cardiac biomarker tests often involve significant costs. These expenses can be a barrier, particularly in low-resource settings, limiting the accessibility of such tests to a broader patient population.

Regulatory Hurdles and Approval Processes

The approval process for new diagnostic biomarkers can be lengthy and complex, involving rigorous clinical trials and regulatory reviews. This can delay the introduction of innovative tests to the market, hindering timely access to new diagnostic options.

Limited Awareness in Emerging Markets

In many emerging economies, there is limited awareness and understanding of the importance of cardiac biomarkers in diagnosing heart diseases. This lack of awareness can result in underutilization of available diagnostic tests, affecting early detection and treatment outcomes.

Expansion of Point-of-Care Testing

The growing preference for point-of-care testing, which offers rapid results and convenience, presents significant opportunities for market expansion. Innovations in portable diagnostic devices and mobile health applications are facilitating the widespread adoption of point-of-care testing, particularly in remote and underserved areas.

Market Segmentation

Based on the type, the market is segmented into troponins (I and T), creatine kinase-MB (CK-MB), myoglobin, natriuretic peptides (BNP and NT-proBNP), and ischemia-modified albumin (IMA).
Based on the application, the market is segmented into acute coronary syndrome (ACS), myocardial infarction (Heart Attack), congestive heart failure (CHF), and others.
Based on the end-user, the market is segmented into laboratory testing and point-of-care testing.

Troponins (I and T) Largest Segment in the Global Cardiac Biomarker Market

Troponins (I and T) are the largest segment in the cardiac biomarkers market, holding a substantial market share. These biomarkers are critical in diagnosing acute myocardial infarction and assessing the severity of cardiac injury. Their high specificity and sensitivity make them indispensable in clinical settings, contributing to their dominance in the market.

Acute Coronary Syndrome (ACS): A Key Segment in Market Growth

Acute coronary syndrome (ACS) and myocardial infarction (MI) are leading applications in the cardiac biomarker market. In 2024, ACS accounted for 56% of the market share, while MI also held a significant portion. Cardiac troponins, particularly high-sensitivity assays, are pivotal in diagnosing these conditions, enabling rapid and accurate assessment in emergency settings. The increasing prevalence of heart attacks globally underscores the critical role of these biomarkers in timely diagnosis and treatment.

Regional Outlook

The global cardiac biomarker industry is further divided by region, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

High Incidence of Cardiovascular Diseases (CVDs) in Asia-Pacific

The Asia-Pacific cardiac biomarker market is witnessing rapid growth due to the region's accelerated growth. China faces a significant burden of cardiovascular diseases, with over 330 million people affected, including 11.39 million with coronary heart disease and 8.9 million with heart failure. This high prevalence drives the demand for advanced diagnostic tools, including cardiac biomarkers, to manage and monitor these conditions effectively.

North America Maintains Strong Market Position

North America holds a significant share of the global cardiac biomarker market. The US accounts for the largest revenue share within North America, driven by factors such as a high incidence of heart-related conditions, an aging population, and a robust healthcare system that facilitates the widespread adoption of cardiac biomarker tests. The integration of these biomarkers into personalized medicine strategies further propels their demand, as they assist in identifying individuals at higher risk of adverse cardiac events and tailoring specific treatment plans. Furthermore, the presence of leading diagnostic companies and research institutions in North America contributes to the continuous development and availability of advanced cardiac biomarker tests. These entities play a crucial role in driving innovation and ensuring that the latest diagnostic tools are accessible to healthcare providers and patients alike.

Market Players Outlook

The major companies operating in the global cardiac biomarker market include Abbott Laboratories, Danaher (Beckman Coulter), Roche Diagnostics, Thermo Fisher Scientific, Siemens Healthineers, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

In September 2025, Medcare has launched an AI-powered blood test to detect coronary artery disease early in young adults, addressing the growing number of cardiovascular issues and sudden heart attacks in the MENA and South Asia regions. The test can predict coronary artery disease development with 95% accuracy, offering a low-risk, fast alternative to traditional diagnostics.
In October 2023, Mindray launched two new high-sensitivity troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers, enhancing its portfolio of cardiac biomarkers for diagnosing and managing cardiovascular diseases (CVDs). These biomarkers are essential for early detection, risk stratification, rapid diagnosis, and therapeutic monitoring, aiding in timely clinical decisions, especially for suspected Acute Coronary Syndrome (ACS) and heart failure.

The Report Covers:

Market value data analysis of 2024 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global cardiac biomarker market. Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2023963

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Global Cardiac Biomarker Market Sales Analysis - Type | Application | End-User ($ Million)
Cardiac Biomarker Market Sales Performance of Top Countries
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Cardiac Biomarker Market Trends
- 2.2.2. Market Recommendations

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For Global Cardiac Biomarker Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Global Cardiac Biomarker Market: Impact Analysis
3.3. Market Opportunities

4. Competitive Landscape

4.1. Competitive Dashboard - Cardiac Biomarker Market Revenue and Share by Manufacturers
Cardiac Biomarker Product Comparison Analysis
Top Market Player Ranking Matrix
4.2. Key Company Analysis
- 4.2.1. Abbott Laboratories
  - 4.2.1.1. Overview
  - 4.2.1.2. Product Portfolio
  - 4.2.1.3. Financial Analysis (Subject to Data Availability)
  - 4.2.1.4. SWOT Analysis
  - 4.2.1.5. Business Strategy
- 4.2.2. Danaher Corp. (Beckman Coulter)
  - 4.2.2.1. Overview
  - 4.2.2.2. Product Portfolio
  - 4.2.2.3. Financial Analysis (Subject to Data Availability)
  - 4.2.2.4. SWOT Analysis
  - 4.2.2.5. Business Strategy
- 4.2.3. Roche Diagnostics
  - 4.2.3.1. Overview
  - 4.2.3.2. Product Portfolio
  - 4.2.3.3. Financial Analysis (Subject to Data Availability)
  - 4.2.3.4. SWOT Analysis
  - 4.2.3.5. Business Strategy
- 4.2.4. Thermo Fisher Scientific
  - 4.2.4.1. Overview
  - 4.2.4.2. Product Portfolio
  - 4.2.4.3. Financial Analysis (Subject to Data Availability)
  - 4.2.4.4. SWOT Analysis
  - 4.2.4.5. Business Strategy
- 4.2.5. Siemens Healthineers
  - 4.2.5.1. Overview
  - 4.2.5.2. Product Portfolio
  - 4.2.5.3. Financial Analysis (Subject to Data Availability)
  - 4.2.5.4. SWOT Analysis
  - 4.2.5.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration

5. Global Cardiac Biomarker Market Sales Analysis By Type ($ Million)

5.1. Troponins (I and T)
5.2. Creatine Kinase-MB (CK-MB)
5.3. Myoglobin
5.4. Natriuretic Peptides (BNP and NT-proBNP)
5.5. Ischemia-modified Albumin (IMA)

6. Global Cardiac Biomarker Market Sales Analysis By Application ($ Million)

6.1. Acute Coronary Syndrome (ACS)
6.2. Myocardial Infarction (Heart Attack)
6.3. Congestive Heart Failure (CHF)
6.4. Others

7. Global Cardiac Biomarker Market Sales Analysis By End-User ($ Million)

7.1. Laboratory Testing
7.2. Point-of-Care Testing

8. Regional Analysis

8.1. North American Cardiac Biomarker Market Sales Analysis - Type | Application | End-User ($ Million)
Macroeconomic Factors for North America
- 8.1.1. United States
- 8.1.2. Canada
8.2. European Cardiac Biomarker Market Sales Analysis - Type | Application | End-User ($ Million)
Macroeconomic Factors for Europe
- 8.2.1. UK
- 8.2.2. Germany
- 8.2.3. Italy
- 8.2.4. Spain
- 8.2.5. France
- 8.2.6. Russia
- 8.2.7. Rest of Europe
8.3. Asia-Pacific Cardiac Biomarker Market Sales Analysis - Type | Application | End-User ($ Million)
Macroeconomic Factors for Asia-Pacific
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. South Korea
- 8.3.4. India
- 8.3.5. Australia & New Zealand
- 8.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 8.3.7. Rest of Asia-Pacific
8.4. Rest of the World Cardiac Biomarker Market Sales Analysis - Type | Application | End-User ($ Million)
Macroeconomic Factors for the Rest of the World
- 8.4.1. Latin America
- 8.4.2. Middle East and Africa

9. Company Profiles

9.1. Abbott Laboratories
- 9.1.1. Quick Facts
- 9.1.2. Company Overview
- 9.1.3. Product Portfolio
- 9.1.4. Business Strategies
9.2. Beckton Dickinson and Co.
- 9.2.1. Quick Facts
- 9.2.2. Company Overview
- 9.2.3. Product Portfolio
- 9.2.4. Business Strategies
9.3. bioMerieux SA
- 9.3.1. Quick Facts
- 9.3.2. Company Overview
- 9.3.3. Product Portfolio
- 9.3.4. Business Strategies
9.4. Bio-Rad Laboratories, Inc.
- 9.4.1. Quick Facts
- 9.4.2. Company Overview
- 9.4.3. Product Portfolio
- 9.4.4. Business Strategies
9.5. Creative Diagnostics
- 9.5.1. Quick Facts
- 9.5.2. Company Overview
- 9.5.3. Product Portfolio
- 9.5.4. Business Strategies
9.6. Danaher Corp. (Beckman Coulter)
- 9.6.1. Quick Facts
- 9.6.2. Company Overview
- 9.6.3. Product Portfolio
- 9.6.4. Business Strategies
9.7. DiaSorin S.p.A.
- 9.7.1. Quick Facts
- 9.7.2. Company Overview
- 9.7.3. Product Portfolio
- 9.7.4. Business Strategies
9.8. F. Hoffmann-La Roche Ltd.
- 9.8.1. Quick Facts
- 9.8.2. Company Overview
- 9.8.3. Product Portfolio
- 9.8.4. Business Strategies
9.9. Johnson & Johnson Services Inc.
- 9.9.1. Quick Facts
- 9.9.2. Company Overview
- 9.9.3. Product Portfolio
- 9.9.4. Business Strategies
9.10. LSI Medience Corp.
- 9.10.1. Quick Facts
- 9.10.2. Company Overview
- 9.10.3. Product Portfolio
- 9.10.4. Business Strategies
9.11. LumiraDx Ltd.
- 9.11.1. Quick Facts
- 9.11.2. Company Overview
- 9.11.3. Product Portfolio
- 9.11.4. Business Strategies
9.12. Mindray Medical International Ltd.
- 9.12.1. Quick Facts
- 9.12.2. Company Overview
- 9.12.3. Product Portfolio
- 9.12.4. Business Strategies
9.13. PerkinElmer Inc.
- 9.13.1. Quick Facts
- 9.13.2. Company Overview
- 9.13.3. Product Portfolio
- 9.13.4. Business Strategies
9.14. QuidelOrtho Corp.
- 9.14.1. Quick Facts
- 9.14.2. Company Overview
- 9.14.3. Product Portfolio
- 9.14.4. Business Strategies
9.15. Randox Laboratories Ltd.
- 9.15.1. Quick Facts
- 9.15.2. Company Overview
- 9.15.3. Product Portfolio
- 9.15.4. Business Strategies
9.16. Response Biomedical Corp.
- 9.16.1. Quick Facts
- 9.16.2. Company Overview
- 9.16.3. Product Portfolio
- 9.16.4. Business Strategies
9.17. Siemens Healthineers
- 9.17.1. Quick Facts
- 9.17.2. Company Overview
- 9.17.3. Product Portfolio
- 9.17.4. Business Strategies
9.18. Thermo Fisher Scientific
- 9.18.1. Quick Facts
- 9.18.2. Company Overview
- 9.18.3. Product Portfolio
- 9.18.4. Business Strategies
9.19. Tosoh Corp.
- 9.19.1. Quick Facts
- 9.19.2. Company Overview
- 9.19.3. Product Portfolio
- 9.19.4. Business Strategies
9.20. Trivitron Healthcare
- 9.20.1. Quick Facts
- 9.20.2. Company Overview
- 9.20.3. Product Portfolio
- 9.20.4. Business Strategies